Alimera Sciences Inc.Find Ratings Reports
ALIMERA SCIENCES INC's gross profit margin for the first quarter of its fiscal year 2019 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. ALIMERA SCIENCES INC is extremely liquid. Currently, the Quick Ratio is 2.86 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 92.44% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY19||Q1 FY18|
|Net Sales ($mil)||12.89||9.8|
|Net Income ($mil)||-2.76||-7.68|
|Balance Sheet||Q1 FY19||Q1 FY18|
|Cash & Equiv. ($mil)||13.13||20.29|
|Total Assets ($mil)||52.31||56.12|
|Total Debt ($mil)||38.57||37.75|
|Profitability||Q1 FY19||Q1 FY18|
|Gross Profit Margin||87.59||86.98|
|Return on Assets||-21.9||-40.89|
|Return on Equity||-1774.14||-268.38|
|Debt||Q1 FY19||Q1 FY18|
|Share Data||Q1 FY19||Q1 FY18|
|Shares outstanding (mil)||70.08||69.99|
|Div / share||0.0||0.0|
|Book value / share||0.01||0.12|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||109698.0||93925.0|
SELL. ALIMERA SCIENCES INC's P/E ratio indicates a significant discount compared to an average of 25.83 for the Pharmaceuticals industry and a significant discount compared to the S&P 500 average of 21.73. For additional comparison, its price-to-book ratio of 96.74 indicates a significant premium versus the S&P 500 average of 3.30 and a significant premium versus the industry average of 9.18. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. The valuation analysis reveals that, ALIMERA SCIENCES INC seems to be trading at a discount to investment alternatives.
|ALIM 3.30||Peers 25.83||ALIM NA||Peers 16.49|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
ALIM is trading at a significant discount to its peers.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|ALIM 25.43||Peers 14.75||ALIM NM||Peers 3.00|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ALIM's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
ALIM's negative PEG ratio makes this valuation measure meaningless.
|ALIM 96.74||Peers 9.18||ALIM 181.81||Peers 331.74|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ALIM is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ALIM is expected to significantly trail its peers on the basis of its earnings growth rate.
|ALIM 1.25||Peers 9.63||ALIM 28.03||Peers 8.53|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ALIM is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
ALIM has a sales growth rate that significantly exceeds its peers.